Medicus Clarifies Phase 2 Results for SkinJect Cancer Therapy
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) issued a clarification of previously reported Phase 2 trial results for its SkinJect therapy in nodular basal cell carcinoma, the company said.
Medicus Clarifies Phase 2 Results for SkinJect Cancer Therapy Read More